Whereas Ozempic and different medicine prefer it have confirmed efficient in serving to folks shed some pounds, many acquire it again when the injections cease. A brand new drug targets weight reduction in a different way, resulting in a extra everlasting fat-shedding resolution.
Whereas their formulations are all barely totally different, medicine like Trulicity, Ozempic, and Wegovy are all Glucagon-like peptide-1 (GLP-1) receptor agonists. These medicine work, partially, by slowing the emptying of abdomen contents and growing a way of fullness. The issue, nonetheless, is that while you cease taking the drug, the emotions of fullness fade, and weight acquire can return.
At this yr’s assembly of the European Affiliation for the Research of Diabetes in Vienna, Austria, researchers from Resalis Therapeutics, a biotech firm in Turin, Italy, simply introduced a weight-loss drug that works in a different way. The drug, which is named RES-010, works by using an antisense oligonucleotide, an artificial little bit of generic materials that blocks the motion of an RNA molecule generally known as miR-22. It’s now in part 1 medical trials in people.
Based on the researchers, miR-22 acts as a “grasp controller” of a number of processes associated to weight problems. These embrace the physique’s fat-metabolizing course of, the creation and regulation of mitochondria, and the best way through which the physique’s fats capabilities and is organized (a course of generally known as adipose tissue transforming). When a weekly injection of the drug was given to mice over the course of 5 months, they misplaced 12% extra weight than untreated mice.
Attending to the foundation trigger
Considerably, each teams of mice ate the identical quantity of energy, indicating that RES-010 modified the physique’s metabolism, somewhat than inflicting the mice to easily eat much less. Mainly, it was capable of deal with the foundation reason for weight problems.
“RES-010 works by reprogramming how cells deal with fats and power,” mentioned examine co-author Riccardo Panella, Resalis’ co-founder and CEO. “Somewhat than lowering urge for food, it modifications the best way through which the physique makes use of fat, boosts the manufacturing and exercise of mitochondria, the ‘batteries’ that energy cells, and helps convert white fats, which shops power, into brown fats, which burns it. As a result of it acts on these elementary pathways, weight regain is much less probably.”
One other advantage of RES-010 is that the animal checks revealed that it was capable of goal fats cells solely, whereas sparing lean tissue. This can be a main distinction from GLP-1 receptor agonists, which may trigger the physique to cannibalize lean mass, together with muscle and bone. The checks revealed that non-human primates (NHPs) given RES-010 misplaced 15% of their fats and just one% of their lean mass over 10 weeks. NHPs placed on semaglutide (the drug marketed as Ozempic) alone, they misplaced 16% of their fats mass, but in addition 8% of their lean mass.
“Lean mass, particularly skeletal muscle, is central to power, stamina and blood sugar regulation, and so its loss is probably dangerous,” says Panella.
As a part of the examine, when the animals have been taken off semaglutide, the regained weight. After they got each semaglutide and RES-010, nonetheless, the load loss remained everlasting, even after each medicine have been stopped.
The brand new part 1 medical trial has been underway within the Netherlands since November 2024. The outcomes are anticipated to be reported in early 2026.
Supply: European Association for the Study of Diabetes through EurekAlert
